alanyltyrosine has been researched along with arginyl-glycyl-aspartic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Achilefu, S; Anderson, CJ; Lewis, JS; Wadas, TJ; Wei, L; Welch, MJ; Ye, Y | 1 |
| Conti, PS; Huang, CW; Li, D; Li, Z; Liu, S; Park, R; Shan, H; Yap, LP | 1 |
2 other study(ies) available for alanyltyrosine and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity.
Topics: Animals; Binding, Competitive; Chelating Agents; Dipeptides; Heterocyclic Compounds; Humans; Integrin alphaVbeta3; Male; Melanoma; Mice; Neovascularization, Pathologic; Oligopeptides; Organometallic Compounds; Positron-Emission Tomography; Sarcosine; Staining and Labeling; Tissue Distribution | 2009 |
Efficient construction of PET/fluorescence probe based on sarcophagine cage: an opportunity to integrate diagnosis with treatment.
Topics: Animals; Carbocyanines; Cell Line, Tumor; Chelating Agents; Dipeptides; Female; Fluorescence; Fluorescent Dyes; Humans; Mice; Mice, Nude; Oligopeptides; Organ Specificity; Positron-Emission Tomography; Xenograft Model Antitumor Assays | 2012 |